Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FK-317, a new antitumor antibiotic from Fujisawa

Oct. 11, 1996

U.S. Bioscience and Schering-Plough revise Ethyol agreement

Oct. 4, 1996

VX-853 for MDR reversal receives patent coverage

Oct. 4, 1996

Inhibitors of endothelial cell proliferation from Sumitomo

Oct. 4, 1996

Human Genome Sciences discloses novel approach to malignancy

Oct. 4, 1996

Anticancer MMP inhibitor enters clinical trials

Oct. 4, 1996

Takeda's anticancer drug pipeline reviewed

Sep. 27, 1996

Promising preclinical and clinical results for Genta's lead antisense compound

Sep. 27, 1996

Clinical benefits of p53 gene therapy

Sep. 27, 1996

Antisense compound displays activity in animal models of human cancer

Sep. 27, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...